{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:07:02Z","timestamp":1790165222427,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Gastric cancer is a highly prevalent malignancy with high mortality worldwide. Radical surgical resection remains the cornerstone for achieving long-term survival in patients with locally advanced gastric cancer. In recent years, immune checkpoint inhibitors have been increasingly introduced into the perioperative setting. In locally advanced gastric cancer, immunotherapy shows potential to improve pathological complete response rates and R0 resection rates. However, its overall survival benefit still requires confirmation from high-quality studies. Meanwhile, immune-related inflammatory responses in tumors and lymph nodes induced by immunotherapy may increase uncertainty in imaging evaluation. This complicates preoperative staging and intraoperative assessment. Against this background, whether the extent of D2 lymph node dissection and surgical strategy should be individualized based on response to neoadjuvant immunotherapy remains controversial. This review summarizes recent advances and ongoing controversies regarding surgical strategies and the extent of lymph node dissection in locally advanced gastric cancer in the era of neoadjuvant immunotherapy, aiming to provide references for clinical decision-making.<\/jats:p>","DOI":"10.3389\/fonc.2026.1924559","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:52:21Z","timestamp":1790164341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluation of lymph node dissection and surgical strategy for locally advanced gastric cancer in the era of neoadjuvant immunotherapy: a narrative review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuzhou","family":"Mei","sequence":"first","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B4","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00676-4","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0093","article-title":"MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer","volume":"18","author":"Janjigian","year":"2022","journal-title":"Future Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tgh-24-57","article-title":"KEYNOTE-585: disappointing results for perioperative pembrolizumab in gastric cancer","volume":"10","author":"Ilson","year":"2024","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1186\/s12893-025-03342-5","article-title":"The research progress on the application of ICG fluorescence imaging in robotic D2 lymphadenectomy for gastric cancer: a narrative review","volume":"25","author":"Guo","year":"2025","journal-title":"BMC Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00384-024-04654-3","article-title":"PD-1\/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review","volume":"39","author":"Wu","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/10732748261430581","article-title":"Research progress on tumor-associated macrophages and PD-1\/PD-L1 inhibitors in advanced colorectal cancer","volume":"33","author":"Ning","year":"2026","journal-title":"Cancer Control"},{"key":"B17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12876-025-03968-y","article-title":"The current status and prospects of gut microbiota combined with PD-1\/PD-L1 inhibitors in the treatment of colorectal cancer: a review","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.01.015","article-title":"Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer","volume":"44","author":"Zhao","year":"2026","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0522","article-title":"Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: a randomized clinical trial","volume":"11","author":"Peng","year":"2025","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01606-w","article-title":"Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial","volume":"28","author":"Ma","year":"2025","journal-title":"Gastric Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.296","article-title":"Phase II study of SHR-1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction adenocarcinoma","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.864533","article-title":"Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Lv","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S1192","DOI":"10.1016\/j.annonc.2025.08.2747","article-title":"2127P neoadjuvant low-dose radiotherapy combined with tislelizumab and chemotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma (GAS-Jiangsu 01): a single-arm phase II trial","volume":"36","author":"Li","year":"2025","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: a review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-022-09092-2","article-title":"Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis","volume":"36","author":"Zhao","year":"2022","journal-title":"Surg Endosc"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100217","article-title":"Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial","volume":"2","author":"Xie","year":"2021","journal-title":"Cell Rep Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70070-X","article-title":"Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial","volume":"11","author":"Songun","year":"2010","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690243","article-title":"Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group","volume":"79","author":"Cuschieri","year":"1999","journal-title":"Br J Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejso.2015.10.003","article-title":"Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center","volume":"42","author":"Norero","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2021.03.031","article-title":"D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial","volume":"150","author":"Degiuli","year":"2021","journal-title":"Eur J Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707035","article-title":"D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer","volume":"359","author":"Sasako","year":"2008","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9484","article-title":"Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis","volume":"101","author":"Tsuburaya","year":"2014","journal-title":"Br J Surg"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5359","article-title":"Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial","volume":"321","author":"Yu","year":"2019","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00981-5","article-title":"An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis","volume":"22","author":"Katayama","year":"2019","journal-title":"Gastric Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12356","article-title":"The efficacy of neoadjuvant immunotherapy combined with chemotherapy in elderly patients with gastric cancer: a subgroup analysis of the NEOSUMMIT-01 study","volume":"7","author":"An","year":"2024","journal-title":"Aging Med (Milton)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s13256-021-03200-x","article-title":"Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report","volume":"15","author":"Takami","year":"2021","journal-title":"J Med Case Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.775147","article-title":"Clinical complete remission of an advanced gastric adenocarcinoma after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine: a case report","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.06.012","article-title":"Organ and function preservation in gastrointestinal Malignancies","volume":"35","author":"Sur","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121961","article-title":"An overview of the treatment strategy of esophagogastric junction cancer","volume":"17","author":"Nakagawa","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s12885-015-1529-x","article-title":"TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG)","volume":"15","author":"Leong","year":"2015","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6936","article-title":"Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer","volume":"97","author":"Degiuli","year":"2010","journal-title":"Br J Surg"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.08.019","article-title":"Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion","volume":"60","author":"D'Alterio","year":"2020","journal-title":"Semin Cancer Biol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1924559\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:52:23Z","timestamp":1790164343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1924559\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":56,"alternative-id":["10.3389\/fonc.2026.1924559"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1924559","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1924559"}}